AM

Amicogen, Inc.

Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.

092040 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경상남도 진주시 문산읍 월아산로950번길 14-10 아미코젠 문산 1공장, 진주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Amicogen, Inc. is an industrial biotechnology company founded in 2000 that specializes in the research, development, and production of special enzymes and other bio-new materials. Leveraging its core enzyme technology, the company provides solutions for the pharmaceutical and healthcare sectors. Its business areas include developing functional ingredients for health and nutrition through its KNUTRA brand, producing cell culture media, and offering Contract Development and Manufacturing Organization (CDMO) services for the bioprocess industry. Amicogen is focused on creating sustainable value for human health and the environment through continuous innovation and R&D.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Amicogen, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-18 00:00
Share Issue/Capital Change
전환가액의조정 (제4회차)
Korean 10.6 KB
2025-09-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-20 00:00
Regulatory News Service
불성실공시법인지정 (공시변경)
Korean 6.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.3 MB
2025-08-11 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제6회차 CB)
Korean 5.6 KB
2025-08-01 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 49.8 KB
2025-07-30 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (대여금 청구-취하)
Korean 7.0 KB
2025-07-28 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 7.3 KB
2025-07-25 00:00
Regulatory News Service
불성실공시법인지정예고
Korean 4.9 KB

Automate Your Workflow. Get a real-time feed of all Amicogen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Amicogen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom VLG
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France VETO
Vifor Pharma AG Logo
A global leader in specialty pharmaceuticals for iron deficiency and nephrology.
Switzerland VIFN
ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea 308080
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France FR000
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark VIRO
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany V3V
Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany VVY
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea 082800

Talk to a Data Expert

Have a question? We'll get back to you promptly.